Cefpodoxime is a third-generation cephalosporin antibiotic used in the treatment of various bacterial infections, including gonorrhea, community acquired pneumonia, and sinusitis. Cefpodoxime is an oral third generation cephalosporin antibiotic with effectiveness against most Gram positive and Gram negative bacteria.
- Mechanism
- Curator reviewed
Cefpodoxime is active against a wide spectrum of Gram-positive and Gram-negative bacteria. Cefpodoxime is stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and cephalosporins, due to their production of beta-lactamase, may be susceptible to cefpodoxime. Cefpodoxime is inactivated by certain extended spectrum beta-lactamases. The bactericidal activity of cefpodoxime results from its inhibition of cell wall synthesis. The active metabolite of cefpodoxime binds preferentially to penicillin binding protein 3, which inhibits production of peptidoglycan, the primary constituent of bacterial cell walls.
- Primary indication
- Indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms.Curator reviewed · 23 structured indications
- Formula / weight
- C15H17N5O6S2 · 427.455 g/mol (avg)
- First approval
- Canada, 2006 · United States, 1991
- Code names
- RU 51807
Resolves to
WYUSVOMTXWRGEK-HBWVYFAYSA-NSMILES[H][C@]12SCC(COC)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=OWhat you can answer from here — as of October 03, 2026
Which drugs share a target with Cefpodoxime, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account